Manage your formulary budget
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Stable extended release oral dosage composition comprising loratadine and pseudoephedrine|
|Abstract:||A film-coated extended release oral dosage composition containing the nasal decongestant pseudoephedrine sulfate in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine, and use of the said composition for treating patients showing the signs and symptoms associated with upper respiratory diseases and nasal congestion are disclosed.|
|Inventor(s):||Kwan; Henry K. (Summit, NJ), Liebowitz; Stephen M. (Neshanic Station, NJ)|
|Assignee:||Schering Corporation (Kenilworth, NJ)|
Patent Claim Types:|
see list of patent claims
|Composition; Use; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||161420||<disabled in preview>|
|Australia||5405094||<disabled in preview>|
|Australia||676229||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.